Bioverativ

This page shows the latest Bioverativ news and features for those working in and with pharma, biotech and healthcare.

AZ cuts $1.5bn-plus deal to pass US drug rights to Sobi

The deal represents a major expansion for Sobi, which is currently focused on rare diseases and haemophilia in Europe (the latter through a licensing deal with Bioverativ), with limited penetration into

Latest news

Sanofi gets EU OK for Ablynx flagship drug Cablivi

of Bioverativ earlier this year which added two marketed haemophilia drugs as well as a pipeline of blood disorder products including genome editing drugs and gene therapies.
Dupixent bounce-back helps stem diabetes declines at Sanofi

A bright point was the rare blood disorder business bolted on with the $11.6bn acquisition of Bioverativ, up 15.5% on a pro forma basis to 257m, and Sanofi is
Sanofi poaches Peugeot's finance head

However it has made some promising new acquisitions this year, including haemophilia and blood disorder specialists Bioverativ, which it bought for $11.6bn.
Evotec says Sanofi deal makes it anti-infectives powerhouse

revamp of its pipeline following the acquisitions of Ablynx and Bioverativ.
BioMarin ups the ante for pivotal haemophilia gene therapy trial

In the chase are Spark Therapeutics’ SPK-8011, Pfizer/Sangamo Biosciences’ SB-525 and Shire’s SHP654 - all in phase I/II testing - with uniQure and Sanofi’s Bioverativ unit also

More from news
Approximately 3 fully matching, plus 13 partially matching documents found.

Latest Intelligence

Deal Watch January 2018

Biogen's spin-out, Bioverativ, had not even got past its first anniversary as a Nasdaq-listed company before being snapped up by Sanofi for $11.6bn (although this is not ... only with its rare disease focus but also enhances its portfolio of products for

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

Industry appointments

Rogerio Vivaldi leaves Bioverativ buyout to head up Sigilon. US-based biotech Sigilon aiming to deliver stem cell therapies for diabetes is getting a new leader. ... The firm has managed to poach Bioverativ’s senior executive Rogerio Vivaldi (pictured
Voyager Therapeutics appoints Matthew Ottmer as chief operating officer

the chief executive officer and president of Syntonix Pharmaceuticals - a wholly owned subsidiary of Biogen, now Bioverativ - and vice president of global operations.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Global Business Development Director – Health Education: excellent commission

Client Services Director – Medical Education Agency – North West...: Salary TBC

Account Director – Health Policy – Global Agency: Salary TBC

Account Director, Medical Education: Salary TBC

Associate Director: £75, 000-90, 000

Senior Account Manager: Competitive Salary Offered

Business Director: Competitive Salary Offered

Editorial Assistant Medical Education Agency: £25, 000 - £26, 000

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Account Manager / Senior Account Manager: 35, 000-40, 000

Home-based Senior Project Manager – Independent Med Ed: Salary TBC

Account Director, Healthcare Marketing Agency: Salary TBC

Senior Account Director development role to Business Director, H...: Excellent package

Account Director: Competitive Salary Offered

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Senior Medical Writer: Salary TBC

Medical Writer: Salary TBC

Account Manager / Account Director: Competative

Account Director – Healthcare Marketing – Berks: Salary TBC

Senior Account Manager, Rare Diseases – Medical Communications, ...: Excellent package

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Engagement Expert, Healthcare Brand Communications, London: Excellent package

Subscribe to our email news alerts

PMHub

Add my company

Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

NHS regional footprints: What to expect from 2019...
Not another weight-loss ad: Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up: As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...